NCT06832722 (PROCARD 1b) is a Phase 1, PHASE2 clinical trial of AK1967 (Procizumab) in Shock, Cardiogenic, sponsored by 4TEEN4 Pharmaceuticals GmbH.

Who is sponsoring NCT06832722?

NCT06832722 is sponsored by 4TEEN4 Pharmaceuticals GmbH.

What drugs are being tested in NCT06832722?

Interventions in NCT06832722: AK1967 (Procizumab), Placebo.

What condition does NCT06832722 study?

NCT06832722 studies Shock, Cardiogenic.

Is NCT06832722 still recruiting?

NCT06832722 is currently recruiting now. Last updated 28 January 2026.

Last reviewed 2026-01-28 · How we verify

NCT06832722: PROCARD 1b

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Procizumab (PCZ; AK1967) in Critical Cardiovascular Care

Recruiting now Phase 1, PHASE2 Last updated 28 January 2026

What this trial tests

Phase 1, PHASE2 trial testing AK1967 (Procizumab) in Shock, Cardiogenic in 130 participants. Currently enrolling.

Timeline

13 July 2025

Primary endpoint
31 March 2026

1 April 2026

Quick facts

Lead sponsor	4TEEN4 Pharmaceuticals GmbH
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	130
Start date	13 July 2025
Primary completion	31 March 2026
Estimated completion	1 April 2026
Sites	16 locations across France, Netherlands, Belgium, Poland, Czechia

Drugs / interventions tested

AK1967 (Procizumab) — full drug profile →
Placebo

Conditions studied

Shock, Cardiogenic — all drugs for Shock, Cardiogenic →

Sponsor

4TEEN4 Pharmaceuticals GmbH — full company profile →

Who can join

Adults 18 to 75, any sex, with Shock, Cardiogenic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this Phase 1b trial is to evaluate the safety and tolerability of procizumab, a monoclonal antibody under development for the treatment of cardiogenic shock (CS). CS is a life-threatening hypoperfusion of vital organs that frequently results in death. In addition to safety and tolerability, pharmacokinetics and pharmacodynamics of procizumab are evaluated to define the optimum phase 2 dose (P2D) of procizumab.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates.
van Lier D, Genest M, Picod A, Manicone F, et al · · 2026 · cited 1× · PMID 42166148 · DOI 10.1080/19420862.2026.2672800
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
van Lier D, Mourisse L, Hollander H, Santos K, et al · · 2026 · cited 1× · PMID 42165327 · DOI 10.1080/19420862.2026.2671468
Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3.
Genest M, Van Lier D, Uba TI, Schroeter A, et al · · 2026 · PMID 42165222 · DOI 10.1080/19420862.2026.2675077
Circulating dipeptidyl peptidase 3 and outcomes in acute heart failure: an analysis of the STRONG-HF and CORTAHF studies.
Bruno J, Edwards C, Takaji K, Azibani F, et al · · 2026 · PMID 41834515 · DOI 10.1093/eschf/xvag076
One Enzyme, Many Faces: The Expanding Role of DPP3 in Cardiovascular and Critical Care.
Zakynthinos GE, Kokkinos NK, Tzima IG, Dimeas IE, et al · · 2025 · PMID 41226854 · DOI 10.3390/jcm14217459

Verify or expand the search:

Other trials of AK1967 (Procizumab)

Trials testing the same drug.

NCT06331884 — Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab) · Phase 1 · completed

Other recruiting trials for Shock, Cardiogenic

Currently open trials in the same condition.

NCT07085221 — Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock · NA · recruiting
NCT06766006 — ECMO LEft Ventricle UNloading Strategy · recruiting
NCT05669183 — Hemodynamic Comparison of Peripheral and Central VA ECMO. · recruiting

Other 4TEEN4 Pharmaceuticals GmbH trials

Trials by the same sponsor.

NCT06331884 — Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab) · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06832722 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by 4TEEN4 Pharmaceuticals GmbH
Last refreshed: 28 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06832722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing